A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

A phase I study was performed to determine the safety and pharmacokinetics of XK469R in patients with refractory acute leukemia. The study aimed to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of XK469R given intravenously over 30 to 60 min on days 1, 3, and 5 of a 21...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Stock, Wendy, Undevia, Samir D., Bivins, Carol, Ravandi, Farhad, Odenike, Olatoyosi, Faderl, Stefan, Rich, Elizabeth, Borthakur, Gautam, Godley, Lucy, Verstovsek, Srdan, Artz, Andrew, Wierda, William, Larson, Richard A., Zhang, Yanming, Cortes, Jorge, Ratain, Mark J., Giles, Francis J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4905709/
https://ncbi.nlm.nih.gov/pubmed/18425419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-008-9129-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados